

# APAC on the Rise

Highlights from the white paper **Exploring the Asia-Pacific Clinical Trials Landscape: Asking the Five W’s**




## Introduction

The Asia-Pacific (APAC) region has emerged as a leader in the global clinical trial landscape amid a significant increase in clinical trials and growing international recognition. Several key factors have driven this shift, including a diverse and substantial patient population, cost effectiveness in conducting clinical trials, and a favorable regulatory environment.

## Number and percentage of Phase I-IV trials starting in APAC/RoW, 2019–23

The total number of APAC trial starts increased from 6,736 in 2019 to 7,824 in 2023, with a CAGR of 3%. Some statistics to highlight: 55% of global trials included a trial location in APAC in 2023, and the number of trials initiated in APAC has exceeded those in the rest of the world (RoW) since 2021.



Source: Trialtrove, August 2024

## Number of Phase I-IV trials starts in APAC by trial locations, percentage of APAC trials, and CAGR, 2019–23


China has been the dominant force driving clinical trial activity in the APAC region, hosting 62% of trials in the region. China is also the only major APAC trial location experiencing positive CAGR growth, at 8%.

| Start year | China | Japan | South Korea | India | Australia | Rest of APAC |
|------------|-------|-------|-------------|-------|-----------|--------------|
| 2019       | 3,766 | 909   | 735         | 614   | 674       | 641          |
| 2020       | 4,646 | 875   | 834         | 908   | 745       | 716          |
| 2021       | 5,701 | 1,000 | 996         | 939   | 868       | 780          |
| 2022       | 4,854 | 752   | 819         | 746   | 769       | 607          |
| 2023       | 5,486 | 703   | 603         | 580   | 636       | 510          |
| % in APAC  | 62%   | 11%   | 10%         | 10%   | 9%        | 8%           |
| CAGR       | 8%    | -5%   | -4%         | -1%   | -1%       | -4%          |

Source: Trialtrove, August 2024

## Percentages of trials that initiated in APAC and RoW by therapeutic area, 2019–23

Oncology continues to lead in both the APAC and RoW regions, with a more significant margin in APAC. Note that 30% of trials initiated in the APAC region are oncology trials, while this number decreases to 19% for the RoW.



Source: Trialtrove, August 2024

Discover more about APAC clinical trials trends and what the future looks like for the region in our white paper: **“Exploring the Asia-Pacific Clinical Trials Landscape: Asking the Five W’s”**.

DOWNLOAD NOW



To learn more about the advantages we can deliver to your company, please visit: [Citeline.com](https://Citeline.com) or email: [info@Citeline.com](mailto:info@Citeline.com)